← Leaderboards
Perenlei Enkhbaatar
University Of Texas Med Br Galveston
$5,647,075
Attributed
$10,095,103
Total exposure
4
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.4M · FY2012–23$2M$1.5M$1M$500K$0
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$10,095,103 · 4
By mechanism
R01$10,095,103 · 4
Top collaborators
- Jae Woo Lee5 shared
- Edward R Sherwood5 shared
- Steven Idell4 shared
- Robert O. Williams4 shared
- Marla R Wolfson4 shared
Most similar at University Of Texas Med Br Galveston
Same institution · by research overlap
Others in their field
Top investigators on “Lung”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David Heimbrook · Leidos Biomedical Research, Inc.$372,040,227
- Chanza Baytop · Westat, Inc.$271,217,917
- Richard K. Wilson · Washington University$201,818,043
- Walter John Curran · Thomas Jefferson University$112,093,071
Research focus
LungSheepLiquid SubstanceSeveritiesAntibioticsClinically RelevantDoseSepsisFunctional DisorderPermeabilityPlasmaSeptic ShockAlveolarMessenger RnaBlood VesselsReceptorMorbidity - Disease RateIndexingProteinsResistanceCause Of DeathMortalityPathway InteractionsAgonist
Grant awards (23)
Therapeutic Use of High Molecular Weight Hyaluronic Acid in Acute Lung Injury Following Severe Bacterial Pneumonia or Sepsis$629,119
R01 · FY2023 · HL
Therapeutic Use of High Molecular Weight Hyaluronic Acid in Acute Lung Injury Following Severe Bacterial Pneumonia or Sepsis$153,425
R01 · FY2023 · HL
Therapeutic Use of High Molecular Weight Hyaluronic Acid in Acute Lung Injury Following Severe Bacterial Pneumonia or Sepsis$788,880
R01 · FY2022 · HL
Etiology of Microvascular Changes in Gram-positive Sepsis: Mechanisms and Therapeutic Options$316,000
R01 · FY2022 · GM · contact PI
Therapeutic Use of High Molecular Weight Hyaluronic Acid in Acute Lung Injury Following Severe Bacterial Pneumonia or Sepsis$794,956
R01 · FY2021 · HL
Etiology of Microvascular Changes in Gram-positive Sepsis: Mechanisms and Therapeutic Options$316,000
R01 · FY2021 · GM · contact PI
Therapeutic Use of High Molecular Weight Hyaluronic Acid in Acute Lung Injury Following Severe Bacterial Pneumonia or Sepsis$815,317
R01 · FY2020 · HL
Etiology of Microvascular Changes in Gram-positive Sepsis: Mechanisms and Therapeutic Options$316,000
R01 · FY2020 · GM · contact PI
Etiology of Microvascular Changes in Gram-positive Sepsis: Mechanisms and Therapeutic Options$316,000
R01 · FY2019 · GM · contact PI
Airway Delivery of Fibrinolytic Therapy for ISALI$740,767
R01 · FY2017 · HL
Airway Delivery of Fibrinolytic Therapy for ISALI$747,162
R01 · FY2016 · HL
Augmentation of Innate Anti-Microbial Immunity by TLR4 Agonists$296,459
R01 · FY2016 · GM
Etiology of microvascular changes in Gram-positive sepsis: mechanisms and therape$290,700
R01 · FY2016 · GM · contact PI
Airway Delivery of Fibrinolytic Therapy for ISALI$743,484
R01 · FY2015 · HL
Etiology of microvascular changes in Gram-positive sepsis: mechanisms and therape$290,700
R01 · FY2015 · GM · contact PI
Augmentation of Innate Anti-Microbial Immunity by TLR4 Agonists$150,392
R01 · FY2015 · GM
Augmentation of Innate Anti-Microbial Immunity by TLR4 Agonists$145,877
R01 · FY2015 · GM
Airway Delivery of Fibrinolytic Therapy for ISALI$780,701
R01 · FY2014 · HL
Augmentation of Innate Anti-Microbial Immunity by TLR4 Agonists$295,271
R01 · FY2014 · GM
Etiology of microvascular changes in Gram-positive sepsis: mechanisms and therape$290,700
R01 · FY2014 · GM · contact PI
Augmentation of Innate Anti-Microbial Immunity by TLR4 Agonists$308,190
R01 · FY2013 · GM
Etiology of microvascular changes in Gram-positive sepsis: mechanisms and therape$280,526
R01 · FY2013 · GM · contact PI
Etiology of microvascular changes in Gram-positive sepsis: mechanisms and therape$288,477
R01 · FY2012 · GM · contact PI